Trial · NCT03104400
Adverse events4,272
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 4,272
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | LEUKOPENIA | Blood and lymphatic system disorders | Upadacitinib 15 mg Period 1 (Weeks 1 to 56) | 16 | 430 | 19 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Upadacitinib 30 mg Period 1 (Weeks 1 to 56) | 15 | 423 | 20 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Adalimumab 40 mg Period 1 (Weeks 1 to 56) | 8 | 429 | 10 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Placebo Period 1 (Weeks 1 to 24) | 4 | 423 | 4 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56) | 1 | 188 | 1 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56) | 3 | 190 | 8 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 21 | 378 | 30 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | 10 | 366 | 14 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Adalimumab 40 mg Period 2 (Weeks 56 to 260) | 9 | 366 | 15 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Placebo / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 10 | 177 | 16 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Placebo / Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | 4 | 178 | 5 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Upadacitinib 30 mg / Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 20 | 443 | 23 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Upadacitinib 15 mg Period 1 (Weeks 1 to 56) | 10 | 430 | 15 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Upadacitinib 30 mg Period 1 (Weeks 1 to 56) | 15 | 423 | 17 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Adalimumab 40 mg Period 1 (Weeks 1 to 56) | 1 | 429 | 1 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Placebo Period 1 (Weeks 1 to 24) | 5 | 423 | 5 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Placebo / Upadacitinib 15 mg Period 1 (Weeks 24 to 56) | 1 | 188 | 1 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Placebo / Upadacitinib 30 mg Period 1 (Weeks 24 to 56) | 1 | 190 | 1 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Upadacitinib 15 mg Period 2 (Weeks 56 to 260) | 13 | 378 | 26 |
| other | LYMPHOPENIA | Blood and lymphatic system disorders | Upadacitinib 30 mg Period 2 (Weeks 56 to 260) | 6 | 366 | 9 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03104400/events